Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1432: Enhanced effector responses of regenerated CAR-T cells derived from genome edited iPSCs

View through CrossRef
Abstract Chimeric antigen receptor (CAR) is an artificial protein that provides HLA-independent antigen specificity to T cells. CAR-T therapy has shown remarkable clinical responses especially in hematologic malignancies. But this therapy requires cell preparation for each patient and it cause some limitations for applicability of CAR-T therapy. We have reported regeneration of T cells from iPSCs (Cell Stem Cell. 2013). Since this technology can provide unlimited number of T cells, CAR-T therapy using iPSCs is thought to broaden its applicability. To target solid tumors, it is important to avoid immunosuppressive factors from tumor microenvironment and to exert sufficient cytotoxicity. Tumor reactive T cells are known to fall into anergy state by continuous antigen stimulations. To overcome immunosuppression in tumor microenvironment, enhancement of TCR signaling by modification of genes related to TCR signal is a promising strategy. Recent studies revealed that the efficacy of CAR-iPS-T cells are not equivalent to primary CAR-T cells. To enhance the efficacy of CAR-iPS-T cells and to produce resistant CAR-T cells to immunosuppression, we focused on TCR signaling pathway. We found that antigen reactivity of CAR-iPS-T cells was insufficient compared with primary CAR-T cells. To overcome the weakness of TCR signal, we disrupted genes negatively related to TCR signal and successfully enhanced TCR signal. As a result, genome edited CAR-iPS-T cells could persist longer in vivo and displayed enhanced tumor suppressive function comparable with primary CAR-T cells. Genome edited iPSCs can be a unlimited cell source of enhanced CAR-T cells. These findings indicate that regenerated CAR-T cells derived from genome edited iPSCs would be a promising CAR-T therapy which would overcome immunosuppressive tumor microenvironment. Citation Format: Tatsuki Ueda, Shoichi Iriguchi, Yohei Kawai, Atsutaka Minagawa, Hiroyuki Miyoshi, Seitaro Terakura, Yasushi Uemura, Knut Woltjen, Yuzo Kodama, Hiroshi Seno, Yasumichi Hitoshi, Tetsuya Nakatsura, Koji Tamada, Shin Kaneko. Enhanced effector responses of regenerated CAR-T cells derived from genome edited iPSCs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1432.
Title: Abstract 1432: Enhanced effector responses of regenerated CAR-T cells derived from genome edited iPSCs
Description:
Abstract Chimeric antigen receptor (CAR) is an artificial protein that provides HLA-independent antigen specificity to T cells.
CAR-T therapy has shown remarkable clinical responses especially in hematologic malignancies.
But this therapy requires cell preparation for each patient and it cause some limitations for applicability of CAR-T therapy.
We have reported regeneration of T cells from iPSCs (Cell Stem Cell.
2013).
Since this technology can provide unlimited number of T cells, CAR-T therapy using iPSCs is thought to broaden its applicability.
To target solid tumors, it is important to avoid immunosuppressive factors from tumor microenvironment and to exert sufficient cytotoxicity.
Tumor reactive T cells are known to fall into anergy state by continuous antigen stimulations.
To overcome immunosuppression in tumor microenvironment, enhancement of TCR signaling by modification of genes related to TCR signal is a promising strategy.
Recent studies revealed that the efficacy of CAR-iPS-T cells are not equivalent to primary CAR-T cells.
To enhance the efficacy of CAR-iPS-T cells and to produce resistant CAR-T cells to immunosuppression, we focused on TCR signaling pathway.
We found that antigen reactivity of CAR-iPS-T cells was insufficient compared with primary CAR-T cells.
To overcome the weakness of TCR signal, we disrupted genes negatively related to TCR signal and successfully enhanced TCR signal.
As a result, genome edited CAR-iPS-T cells could persist longer in vivo and displayed enhanced tumor suppressive function comparable with primary CAR-T cells.
Genome edited iPSCs can be a unlimited cell source of enhanced CAR-T cells.
These findings indicate that regenerated CAR-T cells derived from genome edited iPSCs would be a promising CAR-T therapy which would overcome immunosuppressive tumor microenvironment.
Citation Format: Tatsuki Ueda, Shoichi Iriguchi, Yohei Kawai, Atsutaka Minagawa, Hiroyuki Miyoshi, Seitaro Terakura, Yasushi Uemura, Knut Woltjen, Yuzo Kodama, Hiroshi Seno, Yasumichi Hitoshi, Tetsuya Nakatsura, Koji Tamada, Shin Kaneko.
Enhanced effector responses of regenerated CAR-T cells derived from genome edited iPSCs [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA.
Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1432.

Related Results

UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells
UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells
Aplastic anemia (AA) is characterized by a hypoplastic bone marrow associated with low peripheral blood counts. In acquired cases, the immune system promotes hematopoietic stem and...
Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia
Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia
Background: Acute myeloid leukemia (AML) is one of the most common and highly heterogeneous hematological malignancy. The prognosis is poor especially for the elderly patients. For...
Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients
Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients
Chimeric antigen receptor-engineered (CAR)-T cell therapy represents one of the most promising strategies of cancer treatment, and the function and persistence of CAR-T cells in vi...
Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
Background: CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved high response rates in patients with B-cell lymphoma (BCL). However, treatment failure and relapse can ...
Abstract 1777: A non-signaling CAR for gamma-delta (γδ) T cells to preserve healthy tissues
Abstract 1777: A non-signaling CAR for gamma-delta (γδ) T cells to preserve healthy tissues
Abstract Chimeric antigen receptor T cell (CAR-T) therapy for B cell leukemias and lymphomas have shown remarkable responses in the clinic. However, the elimination ...
PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling
PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling
Abstract Background:Acute myeloid leukemia (AML) is an aggressive hematologic malignancy driven by leukemic stem cells (...
Abstract 2550: Generation of CAR-iPS-T cells expressing CD8β
Abstract 2550: Generation of CAR-iPS-T cells expressing CD8β
Abstract Chimeric antigen receptor (CAR) is an artificial protein that provides HLA-independent antigen specificity to T cells. CAR-T therapy has shown remarkable cl...

Back to Top